**INTRODUCTION**

Cocaine use disorder (CUD) is characterized by continued drug use despite clinically significant distress and other negative consequences. Currently, there is no available pharmacological treatment that has proven effective in replicated, randomized, placebo-controlled clinical trials. To remedy this, medication discovery research has prioritized the search for effective CUD medications. Over the past decade, CB1 receptors (CB1Rs) have been given much attention because of their abundant presence in the central nervous system (CNS) [1–4] and critical involvement in addiction [5–7]. Preclinical studies have demonstrated that mice with genetic ablation of CB1Rs can acquire drug self-administration after extensive training but generally tend to self-administer lower amounts of psychostimulants and are less motivated to seek the drug than their control littermates [6–8]. In contrast, cannabinoid receptor agonists such as Δ9-THC, CP55,940 or WIN55,212-2 have been shown to elicit midbrain dopamine (DA) neurons [9], produce conditioned place preference (CPP) [10], enhance electrical brain stimulation reward [11, 12] and trigger reinstatement of extinguished drug seeking [13] under certain experimental conditions, which has been generally believed to be mediated mainly by activation of CB1Rs [5, 11–13].

Given the importance of CB1Rs in drug-related behavior, CB1R antagonists have been proposed as potential therapeutic candidates for the treatment of drug abuse and addiction [14–17]. A number of preclinical studies with rimonabant and AM251, selective CB1R antagonists with inverse agonist profiles, suggested that they reduce self-administration of heroin [18–20], methamphetamine [21, 22], alcohol [23–26], nicotine [27], and to some extent cocaine [7, 28]; but see [29–31]. In addition, pharmacological blockade of CB1Rs can significantly attenuate the development and expression of cocaine-induced CPP [32, 33] and prevent relapse to addictive drug use (including nicotine, alcohol, and psychostimulants [34–42]), making CB1R ligands promising candidates for the treatment of CUD.

Despite CB1R antagonists being effective in reducing drug reward and relapse in experimental animals (for comprehensive reviews, see [5, 43]), CB1R antagonists have significant adverse
side effects including nausea, emesis, depression, and suicidal tendencies in humans [15, 44–48]. As a consequence, clinical trials with CB1R antagonists were abruptly terminated and the US Food and Drug Administration (FDA) decided not to approve CB1R ligands until better safety and efficacy data become available.

Recently, the medication discovery community has shifted research interest to CB1R neutral antagonists presuming that the inverse agonist profile of CB1R antagonists may underlie their unwanted side effects. We and others recently reported that CB1R neutral antagonists such as AM4113 offer attractive prospects for pharmacotherapeutic exploration as they do not produce psychotropic side effects [49–52], nor do they produce aversive or rewarding effects on their own [19]. Here we evaluated the therapeutic potential of PIMSR, a novel CB1R neutral antagonist, for the treatment of CUD, using a series of animal models of drug abuse and addiction. In vitro radioligand binding assays indicate that PIMSR has as high affinity (Ki = 17–57 nM) for human CB1Rs expressed in cultured HEK cells as does rimonabant (Ki = 1.8–18 nM) [53]. Computational molecular modeling (CB1R docking) and Ca++ channel assays indicate that PIMSR is able to block WIN55,212-2-induced inhibition of Ca++ influx, while itself failing to alter Ca++ influx [53]. PIMSR also stabilizes both the active and inactive states of CB1Rs, revealing the molecular interactions that mechanistically confer the property of neutral antagonism [53]. Electrophysiological assays indicate that co-administration of PIMSR can reverse the inhibitory effects of Δ9-THC or synthetic cannabinoids (AM2201, AM018) on excitatory glutamate transmission in the hippocampus [54]. Pharmacodynamic assays indicate that PIMSR displays relatively low brain penetration — reflected by a brain: plasma concentration ratio of 0.24 after intraperitoneal (i.p.) administration of 10 mg/kg [55]. Importantly, systemic administration of PIMSR significantly reduces body weight, food intake, and adiposity as well as improving glycemic control and lipid homeostasis in high-fat diet-induced obese mice, but also shows increased alanine transaminase (ALT) and liver weight as markers of liver injury with chronic administration [55]. This is unlikely due to neutral CB1R antagonism itself since other neutral antagonists (AM6545) do not produce liver injury or other unwanted side effects [56]. In contrast, repeated (3-day) administration of PIMSR significantly reduced high-dose alcohol-induced acute hepatic injury and steatosis in C57BL/6J mice [55], suggesting the additional potential utility of PIMSR in the treatment of obesity and alcohol use disorder.

Therefore, in the present study, we first systematically evaluated PIMSR’s pharmacological efficacy in reducing cocaine-taking and cocaine-seeking behavior in experimental animals, and then explored the underlying neural mechanisms using electrophysiological, optogenetic, and transgenic approaches. We found that PIMSR reduces cocaine reward and relapse by inhibition of the mesolimbic DA system via both CB1R and non-CB1R mechanisms.

MATERIALS AND METHODS

Animals
Subjects consisted of 48 male Long-Evans rats (purchased from Charles River Laboratories, Frederick, MD), 42 male and female wildtype (C57/BL6J) mice, and 15 heterozygous DAT-cre mice (breeders purchased from Jackson Laboratory, Bar Harbor, ME; B6.SJL-Slc6a3tm1.1(Cre)Bkmn; stock # 006660), aged 4–24 weeks. Rats and mice were chosen based on the availability of the test drug (PIMSR), transgenic animals (DAT-cre), and equipment systems (rat electrical ICSS vs. mouse optical ICSS) in the laboratory. To the best of our knowledge, there are no reports of sex differences in animal behavioral responses to PIMSR. Animals were housed in climate-controlled animal colony rooms on a reversed light-dark cycle (lights on at 7:00 p.m., lights off at 7:00 a.m.) with free access to food and water throughout the study. The housing conditions and animal care were consistent with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). All experimental procedures were approved by the National Institute on Drug Abuse Animal Care and Use Committee.

Exp. 1: Cocaine self-administration and cue-induced reinstatement of drug seeking in rats. Intravenous catheterization surgery and cocaine self-administration procedures were performed as described previously [19, 28]. After stable cocaine self-administration was achieved, the effects of PIMSR (3, 10, 30 mg/kg, i.p.) or vehicle (equal injection volume of 5% Kolliphor EL) on cocaine self-administration under fixed-ratio (FR1, FR5), progressive-ratio (PR), and multiple cocaine dose conditions were evaluated. In addition, the effects of PIMSR on cue-induced reinstatement were also evaluated in separate groups of rats (see more details in the S.I.).

Exp. 2: Oral sucrose self-administration in mice. Procedures for oral sucrose self-administration in mice were the same as we reported previously [57]. This experiment was designed to determine whether the same doses of PIMSR inhibit non-drug reinforced behavior (see experimental details in the S.I.).

Exp. 3: PIMSR-induced place conditioning in mice. This experiment was designed to determine whether PIMSR itself is rewarding or aversive. The experimental details are provided in the S.I.

Exp. 4: Electrical intracranial self-stimulation (ICSS) in rats. To determine the neural mechanisms underlying PIMSR’s action, we observed the effects of PIMSR on reinstrumental self-stimulation (ICSS) behavior in the presence or absence of cocaine. The experimental procedures are the same as we reported previously [12] (also see the S.I. for more details).

Exp. 5: Optogenetic intracranial self-stimulation (ICSS) in DAT-Cre mice. To determine whether DA-dependent and CB1 receptor-dependent mechanisms underlie the effects of PIMSR on cocaine self-administration and brain-stimulation reward, we measured the effects of PIMSR on Δ9-THC- or ACEA-induced changes in ICSS maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice expressing Cre-recombinase under the DA transporter (DAT) promoter. The optical ICSS procedures are the same as we reported previously [58] (see details in the S.I.).

Exp. 6: Δ9-THC-induced tetrad effects in mice. Lastly, we examined the ability of PIMSR to antagonize high dose Δ9-THC-induced classical cannabinoids tetrad effects—analgesia, hypothermia, catalepsy and immobility in mice. The procedures for the measurement of Δ9-THC-induced tetrad effects are the same as we reported previously [59] (see the S.I. for details).

Data analysis
All values were presented as means ± SEM. Animal group sizes were chosen based on a power analysis (n = 6–12 per group) and extensive previous experience with the animal models used. No data points were excluded from the analysis in any experiment. The investigators were blinded to the group allocation during the experiments and when assessing the outcome. Where a variation in group size occurred, this was due to animals being dropped from the experiment due to obstruction or clogging of i.v. catheters.

To validate the use of parametric statistics, we performed a Shapiro Wilk Test for data normality evaluation and Levene’s test for homogeneity for between-subject ANOVA. The group size (n > 5) is the number of independent values (individual animals), and statistical analysis was done using these independent values. One-way or two-way repeated-measures analysis of variance (RM ANOVA) was used to evaluate the effects of PIMSR on cocaine or sucrose self-administration, cue-induced reinstatement, or cannabinoid-induced changes in oICSS. The post-hoc group comparisons were conducted only if the ANOVA F value achieved p < 0.05. Estimation statistics were used when necessary (when data were not normally distributed (www.estimationstats.com). The value of p < 0.05 was used to indicate statistically significant differences among or between groups.

RESULTS

PIMSR fails to alter cocaine self-administration under FR1 reinforcement

We first examined the effects of PIMSR on cocaine self-administration maintained by cocaine (0.5 mg/kg/infusion) under FR1 reinforcement. Figure 1A shows the total numbers of cocaine administrations maintained by cocaine (0.5 mg/kg/infusion) under FR1 reinforcement procedures were performed as described previously [19, 28]. After stable cocaine self-administration was achieved, the effects of PIMSR (3, 10, 30 mg/kg, i.p.) or vehicle (equal injection volume of 5% Kolliphor EL) on cocaine self-administration under fixed-ratio (FR1, FR5), progressive-ratio (PR), and multiple cocaine dose conditions were evaluated. In addition, the effects of PIMSR on cue-induced reinstatement were also evaluated in separate groups of rats (see more details in the S.I.).
We then assessed the pharmacological efficacy of PIMSR on a full dose range (0.5, 0.25, 0.125, 0.06, 0.03 mg/kg/infusion) of cocaine self-administration under a higher FR (FR2) requirement. We observed a typical inverted U-shaped dose-response curve for cocaine self-administration after vehicle treatment (Fig. 1C).

Next, we examined the effects of PIMSR on cocaine self-administration by PR reinforcement. To determine whether PIMSR reduces motivation to seek cocaine, we examined the effects of PIMSR on cocaine self-administration under PR reinforcement in a separate group of rats (n = 8). Systemic treatment with PIMSR (3, 10, or 30 mg/kg) dose-dependently decreased cocaine self-administration maintained by lower doses (<0.5 mg/kg/infusion) of cocaine under FR2 reinforcement and shifted the cocaine dose-response curve downward. A two-way ANOVA revealed a significant cocaine dose × PIMSR treatment interaction (F_{15,140} = 3.19, p < 0.05). Post-hoc Tukey tests for multiple group comparisons revealed that the 30 mg/kg dose of PIMSR significantly reduced self-administration of cocaine doses from 0.03 to 0.12 mg/kg/infusion, while the 10 mg/kg dose of PIMSR significantly reduced self-administration of cocaine doses from 0.06 to 0.12 mg/kg/infusion. PIMSR caused dose-dependent reductions in overall cocaine intake (i.e., sum of cocaine intake under the different doses of cocaine, mg/kg/session), as shown in Fig. 1D. A one-way ANOVA revealed a significant PIMSR treatment main effect (F_{3,28} = 6.4, p < 0.01) with 10 and 30 mg/kg being the effective doses.

**PIMSR reduces motivation for cocaine as determined by self-administration by PR reinforcement**

To determine whether PIMSR reduces motivation to seek cocaine, we examined the effects of PIMSR on cocaine self-administration under PR reinforcement. Figure 2A shows that rats in all dose groups displayed similar baseline (before PIMSR treatment) cocaine infusions, while PIMSR produced a dose-dependent reduction in the number of cocaine infusions under PR reinforcement. A two-way ANOVA revealed a significant PIMSR dose main effect (F_{3,24} = 2.88, p < 0.05). Post-hoc individual group comparisons revealed a significant reduction in the number of cocaine infusions following 30 mg/kg PIMSR (p < 0.05, Fig. 2A). Similarly, PIMSR also produced a dose-dependent reduction in break point for cocaine-taking behavior. A two-way ANOVA revealed a significant PIMSR dose main effect (F_{3,24} = 3.04, p < 0.05).

**PIMSR reduces low-dose cocaine self-administration under FR2 reinforcement**

We then assessed the pharmacological efficacy of PIMSR on a full dose range (0.5, 0.25, 0.125, 0.06, 0.03 mg/kg/infusion) of cocaine self-administration under a higher FR (FR2) requirement. We observed a typical inverted U-shaped dose-response curve for cocaine self-administration after vehicle treatment (Fig. 1C).
Post hoc individual group comparisons revealed a significant reduction in break point following 30 mg/kg PIMSR (p < 0.05, Fig. 2B), suggesting that PIMSR (at a sufficiently high dose) was effective in attenuating animals’ motivation for cocaine.

**PIMSR reduces oral sucrose self-administration**

To determine whether the PIMSR actions observed above are drug- or cocaine-specific, we observed the effects of PIMSR on oral sucrose self-administration in mice. We chose mice in this experiment because of the limited drug source. We found that PIMSR, at 10 and 30 mg/kg, also significantly reduced sucrose self-administration (Fig. 2C). Two-way RM ANOVA revealed a significant PIMSR treatment main effect (F(1, 5) = 21.32, p < 0.01). Post-hoc individual group comparisons revealed a significant reduction (p < 0.001) in sucrose deliveries after 10 or 30 mg/kg PIMSR when compared to the vehicle control group. Figure 2D shows the active and inactive lever responses for sucrose reward. Two-way ANOVA revealed a significant difference (F(1, 26) = 48.59, p < 0.001), inactive vs. inactive lever response main effect (F(1, 26) = 48.59, p < 0.001), and a significant PIMSR x lever response interaction (F(1, 26) = 5.35, p < 0.01). Post-hoc individual group comparisons revealed a significant reduction in cue-induced active lever responding after 10 mg/kg or 30 mg/kg (p < 0.001), but not 3 mg/kg, PIMSR pretreatment. These findings suggest that PIMSR has therapeutic potential for relapse prevention.

**PIMSR is neither rewarding nor aversive in mice**

We then used CPP to examine whether PIMSR itself has similar aversive or depressive effects as rimonabant. Figure 4A shows the general experimental procedures. PIMSR, at 10 or 30 mg/kg, did not produce rewarding or aversive effects as assessed by CPP (Fig. 4B). A two-way RM ANOVA did not reveal a significant main effect (F(1, 16) = 0.33, p > 0.05), inactive vs. inactive lever response main effect (F(1, 16) = 0.28, p > 0.05) or conditioning x dose interaction (F(1, 16) = 0.33, p > 0.05), suggesting a lack of rewarding or aversive effects by PIMSR itself.

**PIMSR attenuates cocaine-enhanced rewarding electrical ICSS**

To determine possible mechanisms underlying PIMSR’s action, we observed the interactions of cocaine and PIMSR on electrical ICSS. Figure 5A shows that electrical stimulation of the medial forebrain bundle (MFB) at the level of the hypothalamus produced robust ICSS behavior (lever-pressing to receive the stimulation).
indicating that PIMSR is neither rewarding nor aversive. Tests) after 10 mg/kg or 30 mg/kg PIMSR-conditioning (procedures.

**B** the presence or absence of PIMSR. Cocaine (2 mg/kg, i.p.)

**Fig. 3** Effects of PIMSR on cue-induced reinstatement of cocaine seeking in rats. **A** General experimental procedures for cue-induced reinstatement of cocaine seeking; **B** The averaged active and inactive lever responses during the last three days of cocaine self-administration, the last three days of extinction, and reinstatement testing. PIMSR, when administered 30 min prior to reinstatement testing, dose-dependently reduced cue-induced reinstatement of cocaine-seeking behavior (n = 6–10 per group). ***p < 0.001, compared to vehicle.

Figure 5B shows representative rate-frequency functions for ICSS, indicating ICSS threshold (θ₀), Ymax, and the effects of cocaine in the presence or absence of PIMSR. Cocaine (2 mg/kg, i.p.) significantly shifted the curve to the left and decreased the ICSS θ₀ value without affecting asymptotic rates of responding (i.e., no change in Ymax level) (Fig. 5B), indicating that cocaine produced an enhancement (additive or synergistic effects) on ICSS. PIMSR (3, 10 or 30 mg/kg, i.p.) pretreatment significantly attenuated cocaine-enhanced ICSS as assessed by θ₀ value (Fig. 5C). A one-way ANOVA with PIMSR dose as a within-subjects factor revealed a significant PIMSR treatment main effect (F_{2,13} = 3.79; p = 0.019). Post-hoc Tukey tests showed that PIMSR significantly attenuated cocaine-enhanced ICSS. Strikingly, PIMSR itself failed to alter the ICSS threshold θ₀ value (Fig. 5D, F_{3,33} = 2.475, p = 0.101), suggesting that PIMSR is not rewarding or aversive by itself, which is consistent with the finding in the CPP experiment and its neutral CB1R antagonist profile.

**PIMSR reduces optical ICSS in DAT-Cre mice**

We then examined whether a DA-dependent mechanism underlies PIMSR action against cocaine’s rewarding effects. Figure 6A illustrates the experimental set-up, demonstrating that AAV-ChR2-eYFP was injected into the VTA ipsilaterally, and optrodes (optical fibers) were surgically implanted 1 mm above the VTA in DAT-cre mice. Figure 6B shows fluorescent ChR2-eYFP and tyrosine hydroxylase (TH) colocalization confirming that ChR2 was expressed in VTA DA neurons. Unexpectedly, PIMSR (10, 30 mg/kg) alone caused significant reductions in optical ICSS maintained by stimulation of VTA DA neurons as shown in Fig. 6C. A two-way RM ANOVA with stimulation frequency and PIMSR dose as within-subjects factors revealed significant main effects of PIMSR dose (F_{2,14} = 12.73, p < 0.001), frequency (F_{3,33} = 92.47, p < 0.001) and a stimulation frequency × PIMSR interaction (F_{10,70} = 3.41, p < 0.001). Post-hoc Tukey tests for multiple group comparisons revealed that 10 or 30 mg/kg PIMSR were effective in attenuating oICSS responding (p < 0.05).

**PIMSR attenuates Δ⁹-THC-induced reduction of oICSS in DAT-cre mice**

Next, we examined whether PIMSR is able to block the action produced by Δ⁹-THC using oICSS. We have previously demonstrated that Δ⁹-THC inhibits oICSS caused by optical stimulation of VTA DA neurons [60] in mice. In line with these findings, systemic administration of Δ⁹-THC, at 3.5 mg/kg, significantly inhibited oICSS in DAT-cre mice (Fig. 6D). A two-way RM ANOVA revealed a significant Δ⁹-THC treatment main effect (F_{3,33} = 11.65, p < 0.001). Unexpectedly, pretreatment with PIMSR (30 min prior to Δ⁹-THC) failed to effectively block Δ⁹-THC-induced reduction in oICSS (Fig. 6F). A two-way RM ANOVA with frequency and treatment as within-subjects factors revealed significant main effects of treatment (Fig. 6E, F_{3,18} = 18.07, p < 0.001) and stimulation frequency (F_{3,30} = 33.27, p < 0.001) and a significant frequency × treatment interaction (F_{9,90} = 6.40, p < 0.001). Post-hoc Tukey tests for multiple group comparisons revealed attenuated responding in the groups administered 3.5 mg/kg Δ⁹-THC in the presence or absence of PIMSR (Fig. 6E).

Given that PIMSR displayed a trend toward reduction in Δ⁹-THC action in a dose-dependent manner, we then re-analyzed the data using the area under curve (AUC) for the data shown in Fig. 5E. We found that PIMSR pretreatment produced a significant reduction in Δ⁹-THC’s action on oICSS (Fig. 6F). One-way RM ANOVA revealed a significant PIMSR treatment main effect (F_{3,18} = 24.34, p < 0.001). Post-hoc individual group comparisons revealed a significant reduction in Δ⁹-THC action on oICSS after 30 mg/kg PIMSR pretreatment, suggesting that a CB1R mechanism at least in part underlies Δ⁹-THC-induced attenuation of oICSS.

**PIMSR attenuates ACEA-induced reduction of oICSS in DAT-cre mice**

To further explore this finding, we examined the effects of PIMSR pretreatment on ACEA (a selective CB1R agonist) induced reduction of oICSS. Figure 6G, H shows that ACEA, at 3 mg/kg, produced a significant reduction in oICSS, an effect similar to that which we reported previously [60]. Pretreatment with PIMSR, at 3 mg/kg, significantly blocked the action produced by ACEA, although this blockade effect is not PIMSR dose-dependent. A two-way RM ANOVA for the data shown in Fig. 6G revealed a significant PIMSR

---

**Fig. 4** PIMSR-induced CPP or CPA in mice. **A** General CPP procedures. B The CPP score (i.e., the averaged value of the two tests) after 10 mg/kg or 30 mg/kg PIMSR-conditioning (n = 9), indicating that PIMSR is neither rewarding nor aversive.
treatment main effect \((F_{4, 20} = 3.21, p < 0.05)\), stimulation frequency main effect \((F_{2, 25} = 8.68, p < 0.001)\), and treatment \(	imes\) frequency interaction \((F_{20, 100} = 2.95, p < 0.001)\). One-way ANOVA for the AUC data shown in Fig. 6H also revealed a significant PIMSR treatment main effect \((F_{4, 20} = 7.83, p < 0.001)\). Post-hoc individual group comparisons revealed a significant reduction \((p < 0.05)\) in ACHE action after 3 mg/kg, but not 10 mg/kg or 30 mg/kg, PIMSR administration.

**PIMSR fails to block \(\Delta^2\)-THC-induced tetrad effects in mice**

Lastly, we examined whether PIMSR antagonizes the effects of \(\Delta^2\)-THC in the tetrad test. As shown in Fig. S1, \(\Delta^2\)-THC, at 10 mg/kg or 30 mg/kg (i.p.), produced characteristic cannabinomimetic effects — hypothermia, analgesia, catalepsy, and immobility in wildtype mice. Systemic pretreatment with PIMSR (10 mg/kg, i.p.) failed to block \(\Delta^2\)-THC-induced analgesia, catalepsy, hypothermia, and immobility, suggesting that PIMSR, at the dose tested, does not exert a clear CB1R antagonist behavioral profile. This finding suggests that higher doses of PIMSR may be required to block such high dose \(\Delta^2\)-THC-induced tetrad effects or other non-CB1R-mediated mechanisms may be involved in \(\Delta^2\)-THC’s action(s) in the tetrad test [59].

**DISCUSSION**

In the present study, we demonstrate that PIMSR failed to alter cocaine self-administration under a low cost (FR1) and high payoff (i.e., high dose cocaine — 0.5 mg/kg/infusion) reinforcement schedule, but dose-dependently inhibited cocaine self-administration under high cost (FR5) reinforcement or self-administration maintained by lower doses of cocaine (0.03, 0.06, 0.12, and 0.25 mg/kg/infusion) under a FR2 reinforcement schedule. PIMSR shifted the cocaine dose-response curve downward, and decreased cocaine intake. PIMSR also dose-dependently decreased break-point (a measure of incentive motivation) for cocaine taking under a PR schedule of reinforcement. Cue-induced reinstatement of cocaine-seeking was attenuated by PIMSR pretreatment, suggestive of an ability to reduce relapse. In addition, PIMSR also dose-dependently inhibited oral sucrose self-administration, suggesting that PIMSR action is not cocaine-specific. This is consistent with previous reports that CB1Rs are critically involved in the modulation of body weight, food intake, and energy metabolism [23, 44, 45, 47, 49, 50, 52, 55]. The observed reduction in cocaine (or sucrose) taking and seeking is unlikely caused by PIMSR-induced motoric incapacitation since PIMSR pretreatment failed to alter cocaine self-administration under a FR1 reinforcement schedule or reduce inactive lever responding under multiple experimental conditions. Neither did PIMSR affect \(Y_{max}\) values in electrical ICSS, a reliable indicator of locomotor incapacity. PIMSR alone also failed to produce locomotor impairment as assessed by catalepsy and rotarod locomotor performance. Importantly, PIMSR itself is neither rewarding nor aversive as assessed by CPP/CPA in mice, suggesting that PIMSR may not have abuse potential or produce unpleasant dysphoria in humans.

The above findings are supported by our electrical ICSS data demonstrating that systemic administration of PIMSR significantly reduced cocaine-enhanced ICSS. The anti-reward effects of PIMSR indicate that the mesolimbic DA system could be its target. Importantly, PIMSR by itself failed to alter electrical ICSS in rats and as such may not produce unwanted side effects such as depressed mood.

**CB1R antagonists and inverse agonists for cocaine use disorder**

As mentioned above, CB1R full antagonists with inverse agonist profiles (such as SR141716A, AM251, and taranabant) were once thought to be promising candidates for the treatment of substance use disorders [5, 43, 61]. Indeed, SR141716A (commonly known as rimonabant) was shown to effectively reduce cocaine-induced hyperlocomotion [62], cocaine sensitization [30, 63], cocaine-induced CPP [64], and cue- or drug-induced, but not stress-induced reinstatement of cocaine seeking [30, 34, 39].
Fig. 6 Effects of PIMSR on oICSS maintained by optical stimulation of VTA DA neurons in DAT-Cre mice. A A diagram showing the experimental methods for oICSS. B Representative images of TH-immunostaining (red) and fluorescent ChR2-eYFP expression (green) in the VTA, illustrating TH and ChR2-eYFP colocalization in VTA DA neurons. C Systemic administration of PIMSR inhibited optical ICSS \((n = 8)\). D \(\Delta^9\)-THC alone also inhibited oICSS at a high dose (3.5 mg/kg) and shifted the stimulation-response curve downward \((n = 7)\). E Pretreatment with PIMSR failed to significantly alter \(\Delta^9\)-THC-induced reduction in oICSS \((n = 7)\). F However, the AUC assays for the data shown in E revealed a significant reduction in \(\Delta^9\)-THC's action on oICSS after PIMSR pretreatment. G PIMSR also attenuated ACEA-induced reduction in oICSS \((n = 6)\). H The AUC assays for the data shown in G revealed a significant reduction in ACEA action on oICSS after 3 mg/kg PIMSR pretreatment. *\(p < 0.05\), compared to vehicle at each stimulation frequency. #\(p < 0.05\), compared to \(\Delta^9\)-THC or ACEA treatment group.
However, prior work examining the ability of other CB1R ligands to suppress cocaine self-administration has been inconsistent. For example, we have previously demonstrated that AM251 significantly lowered the break-point for cocaine self-administration under PR reinforcement in rats while rimonabant did not [28]. Neither AM251 nor SR141716 altered cocaine self-administration under a FR schedule of reinforcement [28–31, 61], suggesting that AM251 and SR141716A are not efficacious in attenuating cocaine self-administration under low cost (FR1, FR2) and high-payoff (cocaine doses from 0.5 to 1.0 mg/kg/infusion) experimental conditions. Furthermore, although mice with a genetic deletion of CB1Rs (CB1-KO) can acquire cocaine self-administration after extensive training [7, 8], they take less drug relative to wildtype mice [8, 65] and show a significant reduction in PR responding [7], suggesting an important role for CB1Rs in cocaine self-administration.

**CB1R neutral antagonists for cocaine use disorder**

In contrast to CB1R antagonists/inverse agonists, neutral CB1R antagonists appear to be devoid of negative side effects and became a target of interest in medication development research for this reason. We recently demonstrated that AM4113, another CB1R neutral antagonist, inhibited self-administration of heroin, but not cocaine or methamphetamine, under FR2 reinforcement conditions in rats without producing aversion [19]. Others showed that AM4113 reduced alcohol consumption [16] and nicotine intake in rats [52]. In addition, AM4113 has been shown to effectively reduce nicotine [52] and cocaine seeking in rats and non-human primates [27]. During a substitution test, when the drug of abuse (nicotine, Δ9-THC or cocaine) was replaced by AM4113, monkeys failed to self-administer it [27], indicating low abuse liability.

Similar to the findings with AM4113, PIMSR also failed to alter cocaine self-administration maintained by a high dose of cocaine (0.5 mg/kg/infusion) under low effort (FR1) reinforcement conditions. However, when the work demand for cocaine was increased from FR1 to FR5 or the cocaine doses were decreased from 0.5 mg/kg/infusion to 0.25, 0.125, 0.06, or 0.03 mg/kg/infusion, PIMSR dose-dependently inhibited cocaine self-administration under FR and PR reinforcement schedules, suggesting that PIMSR is effective in reducing cocaine's rewarding effects when high doses of cocaine are not freely available. In addition, PIMSR dose-dependently attenuated cue-induced reinstatement of drug-seeking, suggesting that this compound may be also efficacious in attenuating relapse to drug-seeking behavior.

**Rewarding vs. aversive effects of neutral CB1R antagonists**

In the present report, some conflicting findings emerged between electrical ICSS vs. oICSS. Neither PIMSR nor AM4113 have any effect on ICSS in rats [19], which suggests that both neutral CB1R antagonists produce no affective valence on their own. In contrast, a high dose of SR141716A produces significant inhibition of ICSS [19], which aligns with clinical reports demonstrating mood-depressant side effects of SR141716A. However, in the oICSS assay PIMSR produced a mild, but significant, reduction in oICSS maintained by stimulation of VTA DA neurons in DAT-Cre mice, suggestive of an aversive or reward-attenuating effect. Caution is warranted in interpreting this finding for a number of reasons. First, PIMSR inhibition of oICSS may not necessarily equate to a diffuse negative effect on mood as this compound likely acts on CB1Rs expressed in multiple cell types. CB1R blockade on different neuronal phenotypes may have varied or opposite effects on brain reward function. For example, optical stimulation of DA neurons or glutamate neurons within the VTA is rewarding [60, 66, 67], while stimulation of VTA GABA neurons is aversive as assessed by oICSS and optical real-time place preference [58]. It is well known that VTA DA neurons receive both GABAergic and glutamatergic inputs [4, 68] and that CB1Rs are highly expressed on both GABA and glutamate neurons in the VTA and substantia nigra pars compacta (SNc) [66]. Thus, blockade of CB1Rs on both GABA and glutamate neurons by PIMSR would produce opposite effects in the mesolimbic DA system, and therefore, no-net change in DA-dependent behavior. This is supported by our finding that PIMSR is neither rewarding nor aversive in the CPP/CPA paradigm. This may also explain why PIMSR has no effect on electrical ICSS since electrical stimulation activates multiple phenotypes of neuronal fibers in the medial forebrain bundle, and PIMSR’s actions on different neural substrates may counteract each other. Second, PIMSR may not be a highly selective CB1R antagonist. We have recently reported that CB2Rs are highly expressed in midbrain DA neurons [5, 68]. Systemic administration of either CB2R agonists (BCP) or inverse agonists (Xie2-64) produces a significant reduction in oICSS by activation of CB2Rs in DA neurons [69, 70]. Thus, if PIMSR also has a binding affinity for CB2Rs, it would produce an inhibitory effect on oICSS. As such, the above finding implies that the mesolimbic DA system could be a particularly important and responsive target for PIMSR intervention.

**Receptor mechanisms underlying PIMSR effects**

As stated above, computational modeling and in vitro receptor binding and functional assays indicate that PIMSR is a neutral CB1R antagonist [53]. Ex vivo electrophysiological studies have demonstrated that local bath perfusion of PIMSR is able to block cannabinoid Δ9-THC, AM108, AM2201-induced inhibition of presynaptic glutamate release or excitatory synaptic transmission in hippocampal brain slices [54]. In the present study, we found that pretreatment with PIMSR significantly attenuated Δ9-THC- or ACEA-induced reduction in oICSS, suggesting that CB1R blockade, at least in part, underlies cannabinoid action in oICSS and PIMSR-induced reduction in cocaine self-administration, cocaine-enhanced ICSS and cue-induced reinstatement of cocaine-seeking behavior observed in the present experiments.

We note that PIMSR failed to completely block Δ9-THC- or ACEA-induced reduction in oICSS nor did it alter high dose (10, 30 mg/kg) Δ9-THC-induced tetrad effects in mice. One possibility is that Δ9-THC is not a selective CB1R agonist. It also binds to other cannabinoid receptors such as CB2, GPR55, and PPAR receptors [59, 69]. This may in part explain why PIMSR, a selective CB1R antagonist, cannot completely block Δ9-THC’s action. Another possibility is that in addition to binding to CB1Rs [53], PIMSR may also bind to other non-CB1 receptors at high doses, producing a reduction in DA-dependent oICSS that compromises the action produced by the blockade of CB1Rs. A third possibility is that PIMSR may be metabolized faster in rodents, and therefore, it may be difficult to maintain sufficient PIMSR levels to block CB1Rs in the brain. This is supported by tissue distribution assays demonstrating that following an acute i.p. dosing of 10 mg/kg, extremely high levels of PIMSR were found in the liver and in fat tissue, while a markedly lower level of PIMSR was found in the brain (brain:plasma concentration ratio of 0.24) [55]. Thus, more studies are needed to further assess PIMSR’s potential off targets and its pharmacokinetic profiles in other species such as rats, nonhuman primates—including oral bioavailability and brain penetration ability.

In summary, the present study demonstrates that the neutral CB1R antagonist PIMSR produces significant inhibitory effects on cocaine self-administration, cocaine-enhanced brain-stimulation reward, and cue-induced reinstatement of drug-seeking, suggesting that PIMSR could be a candidate for the treatment of cocaine use disorder. Given the poor outcome of CB1R antagonists/inverse agonists in clinical trials, a thorough investigation and validation of PIMSR’s efficacy and safety across preclinical and clinical trials are recommended.
DATA AVAILABILITY
All data are available within the article or its supplementary material.

REFERENCES
1. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932–6.
2. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1992;48:655–68.
3. Glass M, Faull RLM, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318.
4. Mátayás F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund TF, et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action in a rat model of oral endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropsychopharmacology. 2008;54:95–107.
5. Galaj E, Xi Z-X. Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs. 2019;33:1001–30.
6. Cosso G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res. 2001;118:61–5.
7. Soria G, Mendiážabal V, Touriño C, Robledo P, Ledent C, Parmentier M, et al. Lack of CB1 cannabinoid receptor impairment in cocaine self-administration. Neuropsychopharmacology. 2005;30:1670.
8. Xi Z-X, Peng X-Q, Li X, Song R, Zhang H-Y, Liu Q-R, et al. Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. Nat Neurosci. 2011;14:1160–6.
9. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997;8:649–52.
10. Braida D, Issoué S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced condition place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506:63–8.
11. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on hybridization histochemistry. Neuroscience. 1992;48:655.
12. Spiller K, Bi GH, Galaj E, Gardner EL, Xi ZX. Cannabinoid CB1 and CB2 receptor pharmacology. 2005;30:1670.
13. Spencer S, Neuhofer D, Chioma VC, Garcia-Keller C, Schwartz DJ, Allen N, et al. A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318.
14. He X-H, Jordan CJ, Vemuri K, Bi G-H, Zhan J, Gardner EL, et al. Cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology. 2006;183:394–403.
15. Caillet S, Alvarez-Jaimés P, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 2007;27:3695–702.
16. Schindler CW, Reddi GH, Vemuri K, Makiyannis A, Le Foli B, Bergman J, et al. block endocannabinoid and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. Neuropsychopharmacology. 2016;41:2283–93.
17. Lesscher HMB, Hoogveld E, Burbach JPH, van Ree JM, Gerrits MAFA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitisation. Eur Neuropsychopharmacology. 2005;15:531–7.
18. Filip M, Golda A, Zanievska M, McCraey AC, Nowak E, Kolesávicz W, et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioural responses induced by cocaine. Pharam Rep. 2006;58:806–19.
19. Adamczyk P, Mitzkie J, McCraey AC, Filip M, Papp M, Przegaliński E. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cannabinoid abuse behavior in rats. Brain Res. 2012;1444:45–54.
20. Yu L-F, Zhou S-J, Wang X-Y, Liu J-F, Xue Y-X, Jiang W, et al. Effects of cannabinoid CB2 receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice. Behav Brain Res. 2011;217:111–6.
21. Delis F, Polisidis A, Pimenta N, Nomokos GG, Goldberg SR, et al. Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and CB1 receptor antagonism in rats. Int J Neuropsychopharmacol. 2017;20:269–78.
22. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2007;13:1511–4.
23. Anggadityekia J, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology. 2004;29:1470–8.
24. Cohen C, Perrault G, Griebel G, Soubrié P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2005;30:145–55.
25. Diergaardt L, de Vries W, Raasa H, Schoffelmeer ANM, De Vries TJ. Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist rimonabant (SR141716A). Neuropsychopharmacology. 2008;55:712–6.
26. Shoaiib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropsychopharmacology. 2008;54:438–44.
27. Ward SJ, Rosenberg M, Dykstra LA, Walker EA. The CB1 cannabinoid receptor antagonist (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend. 2009;105:248–55.
28. de Bruin NMW, Lange JHM, Kruse CG, Herremans AH, Schoffelmeer ANM, van Drimmelen M, et al. SLV330, a cannabinoid CB1(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res. 2011;217:408–15.
29. Jing L, Qiu Y, Zhang Y, Li J-X. Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 2014;134:251–6.
30. McReynolds JR, Doncheck EM, Vranjkovic O, Ganzman GS, Baker DA, Hillard CJ, et al. CB1 receptor antagonist blocks stress-potentiated reinstatement of cocaine seeking in rats. Psychopharmacology. 2016;233:99–109.
31. Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017;124:73–83.
32. Leschker A, Galaj E, Spiller K, Alcántara R, Soubrié P, et al. Clinical trial assessing the safety and efficacy of the CB1R inverse agonist rimonabant in obese and overweight patients: low-dose study. Int J Obes. 2010;34:1243–54.
48. Tambaro S, Tomasi ML, Bortolato M. Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids. Neuropharmacology. 2013;70:268–77.

49. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2185–93.

50. Salamone JD, McLaughlin PJ, Sink K, Makiyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav. 2007;91:383–8.

51. Järbe TUC, LeMajy BJ, Olszewska T, Vemuri VK, Wood JT, Makiyannis A. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharm Biochem Behav. 2008;91:84–90.

52. Gueye AB, Pyslawsky Y, Trigo JM, Pouilla N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:1–11.

53. Hurst D, Umegio U, Lynch D, Seltzman H, Reggio SH, Hyatt S, et al. Bicyclicpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carbamate oxygens/lysine3:28(192) interaction. J Med Chem. 2006;49:5969–87.

54. Hoffman AF, Lycas MD, Kaczmarczyk JR, Spivak CE, Baumann MH, Lupica CR. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid ‘Spice’ compounds: comparison with Δ9-tetrahydrocannabinol. Addict Biol. 2017;22:390–9.

55. Seltzman HH, Maitra R, Bortoff K, Henson J, Reggio PH, Wesley D, et al. Metabolic profiling of CB1 neutral antagonists. Methods Enzymol. 2017;593:199–215.

56. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT L, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharm. 2010;161:629–42.

57. Bi GH, Galaj E, He Y, Xi ZX. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents. Addict Biol. 2020;25:e12783.

58. Galaj E, Han X, Shen H, Jordan CJ, He Y, Humbug B, et al. Dissecting the role of GABA neurons in the VTA versus SNr in opioid reward. J Neurosci. 2020;40:8853–67.

59. Wang XF, Galaj E, Bi GH, Zhang C, He Y, Zhan J, et al. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: opposite roles of CB1, CB2 versus GPR55 receptors. Br J Pharmacol. 2020;177:1865–80.

60. Humbug BA, Jordan CJ, Zhang H-Y, Shen H, Han X, Bi G-H, et al. Optogenetic brain-stimulation reward: a new procedure to re-evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter-cre mice. Addict Biol. 2021:e13005.

61. Caillé S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci. 2003;18:3145–9.

62. Li X, Hoffman AF, Peng X-Q, Lupica CR, Gardner EL, Xi Z-X. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology. 2009;204:1–11.

63. Marinho EAV, Oliveira-Lima AJ, Yokoyama TS, Santos-Baldaia R, Ribeiro LTC, Baldaia MA, et al. Post-sensitization treatment with rimonabant blocks the expression of cocaine-induced behavioral sensitization and c-Fos protein in mice. Pharm Biochem Behav. 2017;156:16–23.

64. Chaperon F, Soubré P, Puech AJ, Thiebot MH. Involvement of central cannabinoi (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology. 1998;135:324–32.

65. Ward SJ, Walker EA. Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice. Behav Pharm. 2009;20:605–13.

66. Han X, He Y, Bi GH, Zhang H-Y, Song H, Liu Q-R, et al. CB1 receptor activation on Vglut2-expressing glutamatergic neurons underlies Δ9-tetrahydrocannabinol (Δ9-THC)-induced aversive effects in mice. Sci Rep. 2017;7:12315.

67. He Y, Galaj E, Bi G-H, Wang X-F, Gardner E, Xi Z-X. β-Caryophyllene, a dietary terpenoid, inhibits nicotine taking and nicotine seeking in rodents. Br J Pharm. 2020;177:2058–72.

68. Melis M, Pistis M, Persa S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci. 2004;24:53–62.

69. Hempel B, Xi ZX. Receptor mechanisms underlying the CNS effects of cannabinoi: CB1 receptor and beyond. Adv Pharmacol. 2022;93:275–333.

70. Jordan CJ, Feng ZW, Galaj E, Bi GH, Xue Y, Liang Y, et al. Xie2-64, a novel CB2( receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents. Neuropharmacology. 2020;176:108241.

Acknowledgements

We thank the NIDA breeding staff for cultivating the transgenic animals used herein. This research was supported by NIDA IRP (ZIA DA000633-01) and the NIDA Medication Development Program.

Author Contributions

ELG and ZXX designed experiments. EG, BH, AM, BK, GHB, and ZXX performed experiments and/or analyzed data. HHS provided PIMSR. EG, BH, and ZXX supervised the work. EG and ZXX wrote the paper. BH, HHS, and ELG revised the paper.

Funding

Open Access funding provided by the National Institutes of Health (NIH).

Competing interests

The authors declare no competing interests.

Additional Information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-02059-w.

Correspondence

and requests for materials should be addressed to Zheng-Xiong Xi.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022